NATCO Pharma stock has declined 34% over six days due to disappointing Q3 FY25 results, including a 37.4% revenue drop and a ...

Natco Pharma shares nosedived today. Its results were impacted by a sharp decline in the export formulation business.

Natco Pharma stock corrected sharply due to weak Q3 results, but future opportunities like semaglutide offer hope.

The stock plunged 10.80 per cent to hit a 52-week low of Rs 868.25. At this price, it has tumbled 28.63 per cent in two ...

Natco Pharma's Q3 earnings were heavily dented by a sharp drag in its export formulations segment, which accounted for 44 ...

Stock analysts noted Natco Pharma’s missed consensus Q3 estimates on both revenue and Ebitda margin fronts due to lack of ...

The company reported a net profit of ₹1,324 crore, down 37.7% from the previous year's ₹2,127 crore. Natco Pharma shares are ...

Image Source : PIXABAY The counter opened gap down with a loss of 18.96 per cent.

Shares of Natco Pharma tumbled 19.86 per cent to hit a low of Rs 975. The stock saw high trading volume on BSE today.

NATCO Pharma reported a 37.75% decline in Q3 FY2025 net profit, dropping to ₹132.4 crore due to a downturn in formulation ...

NATCO Pharma is a smallcap company. It is a constituent of BSE 500 index. The pharma stock crashed 20 per cent after it ...

During the quarter, contribution from the export formulation business was lower; however, the company expects healthy ...